Cosmo valuation report: GI Genius, Winlevi, and Breezula to drive future growth

Tuesday, May 13, 2025 @ 12:00 am

Cosmo is one of the few SIX-listed biopharma companies with cash resources to fund clinical development and pay dividends due to a strong balance sheet and sustainable revenues from eight marketed products. Growth products GI Genius, Winlevi, Breezula are expected to drive significant growth and margin expansion.

Key catalysts include:

1. Investor Day (1 July 2025)
2. Winlevi CHMP re-examination response (Q3 2025)
3. Breezula 6-month topline results phase III AGA trial (early H2 2025)

Cosmo Valuation Report

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

Pharvaris: Data supports clinical development for bradykinin-mediated angioedema drug

Deucrictibant data shows single-dose durability without symptom reoccurrence in the majority of HAE attacks treated First-ever bradykinin B2 receptor mechanism-on-mechanism prophylactic/on-demand data supports potential for deucrictibant portfolio Clinically validated biomarker assay has potential to eventually expand treatment opportunities of deucrictibant into additional forms of bradykinin-med
June 2, 2025

AlphMol obtained approval from Chinese and American regulatory bodies for auto immune diseases treatment

AlphMol obtained IND approval from both Chinese CDE and American FDA for the leading auto immune pipeline.
June 2, 2025

GlycoEra: USD 130 million for the treatment of autoimmune diseases

Financing led by Novo Holdings with significant support from world-class group of existing and new investors. Proceeds from financing to support development of first-in-class IgG4-targeted protein degrader program through clinical proof-of-concept and the continued advancement of the company’s differentiated precision immunology pipeline.
May 27, 2025

ten23 health: Advisory board in collaboration with St. Gallen Symposium

May 27, 2025

Innosuisse is looking for experts

The Innosuisse Innovation Council is currently looking for qualified experts to assist in reviewing funding applications, supporting innovation projects and implementing various innovation promotion activities. The task of these experts is to evaluate and make recommendations for the approval or rejection of funding applications for innovation projects.
May 26, 2025